NYSE$CNMD
Conmed Corp. · Q3 2025 earnings
Q3 2025 earnings · · After market close · Investor relations
Briefing
CONMED reported Q3 2025, revenue of $337.9M, net income of $6M.
For Q3 2025, CONMED reported revenue of $337.9M, net income of $6M. Management discusses segment performance, capital allocation, and macro risks in the quarterly filing.
- Revenue $337.9M.
- Net income $6M.
- CONMED MD&A covers liquidity, credit, and operating priorities.
Headline financials
Revenue & EPS history
Conmed · Revenue · Quarterly
$338M
Revenue by segment
Conmed · $277M total across 2 segments · Q2 2022
- General Surgery$157M—56.6%
- Orthopedic Surgery$120M—43.4%
Forward guidance
The quarterly filing discusses operating priorities, capital returns, and sector risks.
Tailwinds
- MD&A highlights liquidity, capital, and core business trends.
- Segment commentary supports the earnings narrative.
Headwinds
- Macro, rates, or input costs may pressure near-term margins.
- One-time items can affect year-over-year comparability.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q3 2025
-0.0%
Avg return
Earnings day
+0.4%
Avg return
5 days after
+3.0%
Avg return
30 days after
45%
29 / 65 earnings
Positive
+16.5%
Q1 2025
Best reaction
-18.5%
Q3 2015
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +0.6% | +1.9% | -0.8% | |
| Q4 2025 | -4.0% | +0.3% | +18.9% | |
| Q3 2025 | -0.1% | +0.6% | -9.8% | |
| Q1 2025 | +16.5% | +13.8% | +15.6% | |
| Q4 2024 | -9.0% | -12.1% | -15.2% | |
| Q3 2024 | +5.5% | +9.0% | +14.5% | |
| Q2 2024 | -6.0% | -5.6% | +5.3% | |
| Q1 2024 | -13.2% | -5.7% | +3.9% | |
| Q4 2023 | -11.7% | -13.0% | -15.7% | |
| Q3 2023 | -0.3% | +3.1% | +15.0% | |
| Q2 2023 | -1.6% | +0.8% | -10.1% | |
| Q1 2023 | +11.2% | +9.2% | +2.7% | |
| Q4 2022 | +3.3% | +6.4% | +0.4% | |
| Q3 2022 | -3.3% | -1.0% | +3.2% | |
| Q2 2022 | -2.5% | -4.5% | -10.0% | |
| Q1 2022 | -8.5% | -19.2% | -17.3% | |
| Q4 2021 | +4.9% | +11.0% | +19.6% | |
| Q3 2021 | +1.5% | +2.0% | -5.9% | |
| Q2 2021 | +1.3% | -0.2% | -1.4% | |
| Q1 2021 | +4.8% | +7.0% | +1.5% | |
| Q4 2020 | -4.6% | -6.1% | +3.1% | |
| Q3 2020 | +2.8% | -3.9% | +29.6% | |
| Q2 2020 | +5.5% | -0.4% | +4.8% | |
| Q1 2020 | +9.2% | +0.5% | +8.5% | |
| Q4 2019 | -2.6% | -4.7% | -11.9% | |
| Q3 2019 | +10.4% | +12.9% | +13.7% | |
| Q2 2019 | +7.3% | +4.5% | +15.3% | |
| Q1 2019 | +0.7% | -2.6% | +0.8% | |
| Q4 2018 | +6.1% | +4.9% | +12.8% | |
| Q3 2018 | -0.6% | +1.3% | +0.8% | |
| Q2 2018 | +8.6% | +5.5% | +8.7% | |
| Q1 2018 | +7.2% | +5.3% | +10.7% | |
| Q4 2017 | +10.2% | +7.1% | +6.3% | |
| Q3 2017 | +1.9% | -2.7% | +0.7% | |
| Q2 2017 | -1.3% | +1.3% | -4.1% | |
| Q1 2017 | +4.2% | +6.9% | +7.6% | |
| Q4 2016 | -6.9% | -4.0% | -6.8% | |
| Q3 2016 | +5.0% | +3.3% | +18.3% | |
| Q2 2016 | -17.5% | -16.9% | -17.0% | |
| Q1 2016 | -4.1% | — | — | |
| Q4 2015 | -5.9% | — | — | |
| Q3 2015 | -18.5% | — | — | |
| Q2 2015 | -4.3% | — | — | |
| Q1 2015 | +10.7% | — | — | |
| Q4 2014 | -1.4% | — | — | |
| Q3 2014 | +4.4% | — | — | |
| Q2 2014 | -9.5% | — | — | |
| Q1 2014 | -2.8% | — | — | |
| Q4 2013 | +4.2% | — | — | |
| Q3 2013 | -2.7% | — | — | |
| Q2 2013 | +2.8% | — | — | |
| Q1 2013 | -2.7% | — | — | |
| Q4 2012 | +4.6% | — | — | |
| Q3 2012 | +0.3% | — | — | |
| Q2 2012 | -0.4% | — | — | |
| Q1 2011 | +0.8% | — | — | |
| Q1 2012 | -2.1% | — | — | |
| Q1 2010 | -0.2% | — | — | |
| Q4 2009 | -0.2% | — | — | |
| Q4 2011 | -0.2% | — | — | |
| Q3 2010 | -1.8% | — | — | |
| Q3 2011 | -1.8% | — | — | |
| Q2 2011 | -2.3% | — | — | |
| Q4 2010 | -2.3% | — | — | |
| Q2 2010 | -2.3% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro